FDA broadens Botox use; Four contractors team for drug development;

 @FierceBiotech: Who's the next biotech buyout target? Report | Follow @FierceBiotech

 @JohnCFierce: My own contribution to solving Spain's financial crisis: I just bought a $25 burger. Viva la carne! Follow @JohnCFierce

> Four contractors team for drug development. Article

> The FDA has approved Allergan's anti-wrinkle drug Botox for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity. Allergan release

> Affymax has received a $5 million development milestone payment from Takeda under the companies' deal for Hematide, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. Initiation of Phase III trials in Japan triggered the payment. Affymax release

> Swiss drugmaker Novartis announced a $5 billion bond issue to finance its purchase of eye-care company Alcon. Report

And Finally... Researchers have found that papaya had a dramatic anticancer effect against a broad range of lab-grown tumors, including cancers of the cervix, breast, liver, lung and pancreas. Report

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.